Zon, Robin T., McClean, John, Helman, Douglas, Ansari, Rafat, Picus, Joel, Sandler, Alan, Williams, Stephen D., and Loehrer, Patrick J.
Byline: Robin T. Zon (1), John McClean (2), Douglas Helman (3), Rafat Ansari (1), Joel Picus (4), Alan Sandler (3), Stephen D. Williams (3), Patrick J. Loehrer (3,5) Keywords: altretamine; renal cell carcinoma Abstract: Thirty patients with advanced renal cell carcinoma weretreated on a phase 11 trial with altretamine. Altretamine wasadministered orally at a dosage of 260 mg/m.sup.2 days 1 through14 with cycles repeated every 28 days. Nausea and vomitingwere the most common toxicities. Ten percent (3 of 30)experienced Grade 3 gait abnormalities. None of the thirtyevaluable patients achieved a complete or partial response. Insummary, altretamine did not show antitumor activity in thetreatment of advanced renal cell carcinoma. Author Affiliation: (1) Northern Indian Cancer Research Consortium, South Bend, IN, USA (2) The Cottage Professional Building, Galesburg, USA (3) Indiana University Cancer Center, Indianapolis, USA (4) Washington University/Barnard Cancer Center, St. Louis, MO, USA (5) The Walther Oncology Institute, Indianapolis, IN, USA Article History: Registration Date: 11/10/2004